scholarly journals In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid.

1987 ◽  
Vol 31 (1) ◽  
pp. 132-133 ◽  
Author(s):  
M J Casal ◽  
F C Rodriguez ◽  
M D Luna ◽  
M C Benavente
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Clavulanic Acid ◽  
Mycobacterium Bovis ◽  
Mycobacterium Avium ◽  
Mycobacterium Fortuitum ◽  
Mycobacterium Chelonae ◽  
In Vitro Susceptibility ◽  
Mycobacterium Africanum

scholarly journals Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis – application for identification and susceptibility testing

2006 ◽  
Vol 55 (1) ◽  
pp. 37-42 ◽  
Author(s):  
Jan Rybniker ◽  
Stefanie Kramme ◽  
Pamela L. Small
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Host Range ◽  
Mycobacterium Bovis ◽  
Susceptibility Testing ◽  
Phage Therapy ◽  
Large Range ◽  
Mycobacterium Ulcerans ◽  
Mycobacterium Fortuitum ◽  
Mycobacterium Chelonae ◽  
Replication Assay

The host range of well-characterized mycobacteriophages, such as D29 and TM4, has been determined, together with that of more recently isolated mycobacteriophages, in Mycobacterium ulcerans, Mycobacterium tuberculosis, Mycobacterium bovis BCG, Mycobacterium avium, Mycobacterium marinum, Mycobacterium scrofulaceum, Mycobacterium fortuitum and Mycobacterium chelonae. Here, a set of virulent phages for M. ulcerans, a pathogen with a dramatic increase of incidence over the last decade, is demonstrated. In this work, a mycobacteriophage replication assay was adapted for the identification and rifampicin-susceptibility testing of M. ulcerans. Mycobacteriophages have generated a number of useful tools and enabled insights into mycobacterial genetics. With regard to the neglected pathogen M. ulcerans, the findings presented in this work allow the application of a large range of phage-based vectors and markers. The potential of phage therapy can now be evaluated for this extracellular pathogen.

New Macrolide Antibiotics: Usefulness in Infections Caused by Mycobacteria other Than Mycobacterium Tuberculosis

1994 ◽  
Vol 28 (11) ◽  
pp. 1255-1263 ◽  
Author(s):  
Robert P. Rapp ◽  
Scott A. McCraney ◽  
Norman L. Goodman ◽  
David J. Shaddick
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Antimicrobial Agents ◽  
New Drugs ◽  
Vitro Activity ◽  
Great Promise ◽  
Macrolide Antibiotics ◽  
Mycobacterium Fortuitum ◽  
In Vitro Activity ◽  
Mycobacterium Chelonae

OBJECTIVE: To compare the pharmacology, in vitro activity, and clinical use of the new macrolide antibiotics, azithromycin and clarithromycin, in the treatment of infections caused by mycobacteria other than Mycobacterium tuberculosis. DATA IDENTIFICATION: An English-language literature search using MEDLINE (1987–1994), Index Medicus (1987–1994), Program and abstracts of the 31st (1991) and 32nd (1992) Interscience Conference on Antimicrobial Agents and Chemotherapy, and bibliographic reviews of related textbooks, review articles, and professional society publications. STUDY SELECTION: 105 articles were selected. In vitro and in vivo reports on the pharmacokinetics, microbiology, pharmacology, and effectiveness of clarithromycin and azithromycin were assessed to compare their effectiveness and safety. Emphasis was placed on the use of these new drugs in treating infections caused by Mycobacterium avium complex, Mycobacterium chelonae, and Mycobacterium fortuitum infections. RESULTS: A review of the in vitro activity of the new macrolides revealed moderate to very good activity against many strains of mycobacteria other than M. tuberculosis. Early clinical trials show promising results in pulmonary infections, lymphadenitis, cutaneous infections, and disseminated infections. CONCLUSIONS: The new macrolides, azithromycin and clarithromycin, show great promise for treating infections caused by these acid-fast bacteria. Clarithromycin is recommended as a component of combination therapy for the treatment of M. avium complex infections in patients with AIDS. The development of resistance in patients, particularly when these agents are used alone, has been reported.

scholarly journals In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Yaojie Shen ◽  
Xuyang Wang ◽  
Jialin Jin ◽  
Jing Wu ◽  
Xuelian Zhang ◽  
...  
Keyword(s):  
Public Health Problem ◽  
Drug Susceptibility ◽  
Mycobacterium Abscessus ◽  
Mycobacterium Fortuitum ◽  
In Vitro Susceptibility ◽  
Antitubercular Drugs ◽  
Microdilution Method ◽  
Susceptibility Tests ◽  
Susceptibility Profiles

Objective. Nontuberculous mycobacteria (NTM) cause various diseases in humans and animals. Recently, the prevalence of NTM-related disease has been on the rise, becoming an emerging public health problem. The aim of this study was to determine the antibiotic susceptibility profiles of clinical isolates of Mycobacterium abscessus and Mycobacterium fortuitum. Methods. We performed susceptibility tests on 37 clinical NTM isolates to 30 antibiotics with the microdilution method recommended by the Clinical and Laboratory Standards Institute. Results. Both M. abscessus and M. fortuitum were highly resistant to antitubercular drugs such as isoniazid, rifampin, ethambutol, clofazimine, ethionamide, and rifabutin. M. abscessus showed the lowest resistant rates to cefoxitin (10%), azithromycin (10%), amikacin (10%), and clarithromycin (20%) and very high resistant to sulfamethoxazole, vancomycin, oxacillin, clindamycin, and all fluoroquinolones. M. fortuitum showed low resistance to tigecycline (0%), tetracycline (0%), cefmetazole (12%), imipenem (12%), linezolid (18%), and the aminoglycosides amikacin (0%), tobramycin (0%), neomycin (0%), and gentamycin (24%). Conclusion. Amikacin, cefoxitin, and azithromycin have the highest in vitro activity against M. abscessus. Isolates of M. fortuitum need to be individually evaluated for drug susceptibility before choosing an effective antimicrobial regimen for treatment of infections.

Antimicrobial Susceptibility of Subgingival Bacterial Flora in Cats with Gingivitis

1995 ◽  
Vol 12 (4) ◽  
pp. 157-160 ◽  
Author(s):  
C.E. Harvey ◽  
C. Thornsberry ◽  
B.R. Miller ◽  
F. S. Shofer
Keyword(s):  
Clavulanic Acid ◽  
Antimicrobial Susceptibility ◽  
Antimicrobial Agents ◽  
Bacterial Flora ◽  
In Vitro Susceptibility ◽  
Amoxicillin Clavulanic Acid ◽  
Aerobic And Anaerobic

The aerobic and anaerobic flora from gingival pockets of 40 cats with established gingivitis were cultured. The susceptibility of each isolate to four antimicrobial agents currently approved for use in cats (amoxicillin-clavulanic acid; clindamycin; cefadroxil; enrofloxacin) was determined. Amoxicillin-clavulanic acid (Clavamox®) had the highest in-vitro susceptibility against all isolates (92%) and all anaerobes (99% [co-equal with clindamycin]) tested; enrofloxacin (Baytril®) had the highest in-vitro susceptibility against all aerobes (90%) tested.

Sign in / Sign up

Export Citation Format

Share Document